Introduction
Acylcarnitines are intermediates in fatty acid and amino acid breakdown generated from the conversion of acyl-CoA species by the action of carnitine acyltransferases (1) . The formation of carnitine conjugates is crucial for the transport of activated fatty acids (Acyl-CoAs) from the cytosol across the inner mitochondrial membrane into the matrix where fatty acid oxidation takes place. It has now become clear that a net efflux of acylcarnitine species from the mitochondria into the cytosol and ultimately into plasma, is particularly important in situations of impaired fatty acid oxidation to prevent accumulation of potentially toxic acyl-CoA intermediates in the mitochondrium (2, 3) . How acylcarnitines are released into the extracellular space is not known, but changes in plasma and/or urinary acylcarnitine profiles are used to detect disorders in fatty acid and amino acid oxidation (4).
More recently, alterations in plasma acylcarnitine profiles were described as strongly associated with obesity and type 2 diabetes (5-7). A broad spectrum of short-, medium-and long-chain acylcarnitine species is generated from multiple metabolic routes including various fatty acid and amino acid oxidation pathways. A comprehensive quantification that covers as many as possible of these entities is therefore not only important for proper clinical diagnosis of inherited enzymatic impairments but also for basic studies of complex diseases such as the metabolic syndrome.
Acylcarnitine profiles are commonly established by direct infusion electrospray ionization-tandem mass-spectrometry (ESI-MS/MS). This technology does however not allow the discrimination of isomeric acylcarnitine species. Furthermore, isobaric matrix interferences can lead to an overestimation of metabolite concentrations producing false positive results in particular for compounds with low abundance (8) . Although LC-MS/MS methods have been developed for successful separation of isomeric compounds (9) (10) (11) (12) , the identification of the exact compound in the chromatogram often remains elusive. Additionally, the abundance of many species in biological samples is often too low for robust detection and quantification.
We here describe a robust and highly sensitive LC-MS/MS method for comprehensive quantification of an array of acylcarnitine species with a special focus on amino acid-derived intermediates, which often occur at very low concentrations and in isomeric forms. Since alterations in plasma oddby guest, on August 15, 2017 www.jlr.org Downloaded from precipitated and washed three times in cold diethyl ether. Sodium-(s)-β-hydroxyisobutyric acid was first treated with hydrochloric acid to produce the free fatty acid, followed by evaporation of water at 90°C for 30 minutes, before incubation with thionylchloride. For (S)-and (D)-β-hydroxybutyric acid and for (S)-β-hydroxyisobutyric acid, this protocol generated a racemic mixture of both (S)-and (D)-stereoisomers.
Sample preparation and derivatization
10 µl Plasma were dissolved in 100 µl ice-cold methanol containing the internal standard mixture under ultra-sonication to prevent sample aggregation. Dissolved samples were evaporated to dryness in a vacuum concentrator. Tissue samples were first grounded in liquid nitrogen using pestle and mortar. 40 mg of tissue were then extracted using 1800 µl 100% ice-cold methanol and centrifuged at 10.000 g, 4°C for 10 minutes. Finally, internal standard was added to 200 µl of the supernatant, before vacuum-drying the samples.
Acylcarnitines were derivatized to their butyl esters as described by Gucciardi et al. (9) . Briefly, 100 µl n-butanol containing 5% v/v acetyl chloride was added to the dried samples, incubated at 60°C for 20 minutes at 800 rpm (Eppendorf Thermomixer comfort, Eppendorf, Hamburg, Germany) and subsequently evaporated to dryness. Samples were reconstituted in 100 µl (for plasma samples) or 200 µl (for tissue samples) methanol/water and transferred to glass vials.
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS)
The analysis was performed on a triple quadrupole QTRAP5500 LC-MS/MS system (AB Sciex, Framingham, MA, USA), equipped with a 1200 series binary pump, a degasser and a column oven (Agilent, Santa Clara, CA, USA) connected to a HTC pal autosampler (CTC Analytics, Zwingen, Switzerland). A Turbo V ion spray source operating in positive electron spray ionization (ESI) mode was used for ionization. The source settings were: ion spray voltage = 5500 V, heater temperature = by guest, on August 15, 2017 www.jlr.org Downloaded from 600°C, source gas 1 = 50 psi, source gas 2 = 50 psi, curtain gas = 40 psi, and collision gas (CAD) = medium.
Chromatographic separation was achieved on a Zorbax Eclipse XDB-C18 column (length 150 mm, internal diameter 3.0 mm, particle size 3.5 µm, Agilent) at a column temperature of 50°C. Eluent A consisted of 0.1% formic acid, 2.5 mM ammonium acetate and 0.005% heptafluorobutyric acid in water. Eluent B consisted of 0.1% formic acid, 2.5 mM ammonium acetate and 0.005% heptafluorobutyric acid in acetonitrile. Gradient elution was performed with the following program: 100% A (0.5 ml/min) for 0.5 min, a linear decrease to 65% A (0.5 ml/min) for 2.5 min, hold for 3 min, a linear decrease to 40% A (0.5 ml/min) for 3.7 min, a linear decrease to 5% A (0.5 ml/min) for 1 min. Elution was then carried out at 100% B (1 ml/min) for 0.5 min, hold for 7.3 min (1.5 ml/min).
Re-equilibration was finally performed at 100% A (0.5 m/min) for 4 min. The complete running time of the program was 22 minutes. Analytes were measured in scheduled multiple reaction monitoring (total scan time = 0.5 s, scan time window = 0.5 min). Quadrupoles were working at unit resolution.
Calibration and quantification
Calibration was achieved by spiking plasma and liver samples with different quantities of acylcarnitine standards. A ten-point calibration was performed by addition of increasing amounts of each standard and IS as described in the sample preparation section. Calibration curves were constructed and fitted by linear regression without weighting. Data analysis was done using Analyst 
Statistical analysis
Levels of significance between metabolite concentrations in streptozotocin-treated and control mice
were assessed using two-sided independent Student's t-tests.
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Results
Sample extraction and derivatization
Extraction of acylcarnitine species from plasma and tissue samples was achieved using methanol and analytes were derivatized to their butyl esters. Since dicarboxylic acylcarnitines were derivatized at both carboxyl groups (see Figure 1 ), we could discriminate various isobaric acylcarnitines, which have different masses as corresponding butyl esters (e.g. hydroxybutyryl-carnitine (C4-OH-CN, non- 
Acylcarnitine fragmentation
Mass spectrometric analysis of acylcarnitine species was performed using ESI in positive mode and product ion spectra were acquired. Butylation of acylcarnitines (especially of dicarboxylic species) as initially described by Donald Chace in 1997 (15) . A compilation of all acylcarnitine species covered by our method including the corresponding MS parameters is shown in Table 1 .
Chromatographic separation and identification of isomeric acylcarnitine species
Since all acylcarnitines form a similar product ion (m/z 85) and many compounds are isobaric or occur as positional isomers, appropriate chromatographic separation is essential. Chromatographic separation was established using a C18-reversed phase (RP) HPLC column (length: 15 cm, internal diameter: 3.0 mm, particle size: 3.5 µm). We favored a HPLC column over a UPLC column, because larger sample volumes of complex matrices were injected. Peaks were well shaped, sharp (~0.1 min; Figure 2 ) and well separated. A co-elution of analyte and IS was achieved, which is important to compensate for matrix effects and varying ionization efficiencies during gradient elution (16) . The addition of HFBA to the eluents as an ion-pairing reagent (17) improved peak separation and peak sharpness. Addition of ammonium acetate enhanced ionization efficiency. Figure 2A shows a typical chromatogram (TIC) derived from a liver sample containing acylcarnitines ranging from 0 to 18 carbon atoms. We found that retention times increased with the number of carbons and decreased with the number of double bounds. Since >50 mass transitions were required to quantify all metabolites, data were acquired in the scheduled MRM mode to yield more and shorter scan cycles per peak, to facilitate peak integration and data analysis.
Various acylcarnitine isomer species were expected to result from known amino acid and fatty acid breakdown pathways (18) . Indeed, chromatographic separation generated multiple peaks for various for which generally two peaks were found (see Figure 2D ). In contrast, for mono-unsaturated and dicarboxylic acylcarnitines, branched-chain forms eluted later (e.g. crotonyl-carnitine (C4:1-CN) < methacrylyl-carnitine (2-M-C3:1-CN), see Figures 2B and 2C). Furthermore, hydroxy-acylcarnitines
hydroxyhexadecanoyl-carnitine (C16-OH-CN)), displayed two peaks. This was in accordance with previous reports suggesting the presence of L-and D-stereoisomers (9, 11, 19) .
Calibration and quantification
For quantification of metabolite concentrations and to compensate for variation in sample preparation and ionization efficiency, an acylcarnitine standard mixture containing 13 deuterium-labeled acylcarnitine species was added to the samples (Table 2) . Calibration lines were generated by addition of different concentrations of acylcarnitine species to a pool of liver and plasma samples. The ratio between analyte and IS was used for quantification ("stable isotope dilution"). For those analytes where no corresponding IS was available, analyte-IS pairs were selected according to the closest retention times and the best accuracies for these analyte-IS allocations (e.g. nonanoyl-carnitine (C9:0-
. For all analytes and matrices calibration curves were linear and correlation coefficients (r 2 ) were greater than 0.99 ( Table 2) . Limits of detection (LOD)
were determined as the signal-to-noise ratio of three, and limits of quantitation (LOQ) were calculated as the triple fold of the LOD and were sufficient enough for quantification of acylcarnitine species in plasma and liver samples ( Table 2) .
Method validation and sample stabilities
The accuracy of the method was tested in 3 liver and 3 plasma samples by spiking with acylcarnitine standards in concentrations covering the whole calibration range. Accuracies between 81 and 108%
were found for the liver matrix and between 89 and 120% for the plasma matrix (Table 3) , except for the lowest levels of free carnitine in liver tissues for which concentrations were overestimated. Method reproducibility was examined by determining intra-and inter-day precisions in pools of plasma and liver samples. With a few exceptions, intra-and inter-day coefficients of variations for liver and plasma samples were below 10% for high-abundant acylcarnitines (> 0.01 pmol/mg tissue; > 0.01 pmol/µl plasma) and between 10-20% for low-abundant acylcarnitines. Recoveries were calculated as the difference between area ratios of pre-spiked samples (addition of standards before extraction) and post-spiked samples (addition of standards to the methanol extract). Recoveries between 59 and 99%
were found (Supplementary Table 1 ). Matrix effects were determined by comparing the peak areas of acylcarnitine species spiked in matrix samples (three plasma and three liver samples) and corresponding amounts dissolved in methanol at two levels (Supplementary Tables 2 and 3 ). The area ratios of spiked acylcarnitine species in plasma samples ranged between 110 and 120% compared to non-matrix samples. Area ratios of spiked acylcarnitine species in liver were between 85 and 122%, compared to non-matrix samples, with a few exceptions for short-chain species.
To assess sample stability in plasma, samples were stored at room temperature for 1 hour before extraction and peak areas were compared with samples that were directly extracted. Acylcarnitines in plasma remained stable over 1 hour at room temperature. For liver tissue, thawing of samples in three freeze-thaw cycles strongly affected the abundance of various analytes, but post-preparative storage of plasma and liver samples at -20°C showed a high stability of most analytes. See Supplementary Table   4 for a summary on plasma and liver sample stabilities.
Method application
The developed method was applied to plasma and liver samples from streptozotocin-treated insulindeficient and healthy control mice. Streptozotocin (STZ) causes pancreatic beta-cell destruction resulting in insulin-deficient type I diabetes (20) . STZ-treated animals showed very low circulating insulin levels accompanied by a dramatic weight loss and a severe increase in blood glucose levels five days after treatment (see Supplementary Table 5 ).
We found that concentration ranges of acylcarnitine species in plasma and liver were in good agreement with levels reported previously (21) Table 6 provides concentrations of all acylcarnitine species quantified in liver and plasma of healthy and diabetic mice in our study.
Discussion
Acylcarnitines have recently gained considerable interest as markers for impairments in fatty acid and amino acid oxidation associated with the metabolic syndrome (5-7). Moreover, the metabolites were proposed to have predictive quality for disease initiation and progression (5) . Various acylcarnitines occur as positional isomers and many species often appear at very low concentrations. Even though several LC-MS/MS methods have been described for quantification of isomeric acylcarnitine species (9-12), a comprehensive method that covers low-abundant species and includes odd-numbered acylcarnitines is lacking.
We here describe a sensitive and robust method for quantification of individual isomeric acylcarnitine species including low-abundant amino acid-derived forms (see Figure 4 ). In addition, our method includes acylcarnitines with odd-numbered acyl-chain lenghts which gained increased attention recently as metabolite markers in disease states (5, 22, 23 ).
We applied ESI in positive mode for ionization. Collision-induced dissociation produced an intense product ion at m/z 85 for all analytes, which was described to be a specific product ion of acylcarnitine fragmentation (15) . Liquid chromatography with a C18-RP HPLC column allowed the chromatographic separation of isomeric acylcarnitine species and by spiking with reference compounds, we could subsequently assign the individual isomers to the respective peaks. Proper chromatographic separation is mandatory, since positional isomers have similar mass transitions (e.g.
crotonyl-carnitine (C4:1-CN) and methacrylyl-carnitine (2-M-C3:1-CN), m/z 286  m/z 85). In addition, quantification of acylcarnitine concentrations in a direct infusion approach is challenged by potential interfering matrix components which lead to an overestimation of analyte concentrations (9).
Although a separation of un-derivatized acylcarnitine isomers has been described (11) we applied a butylation to achieve an enhanced sensitivity, particularly for dicarboxylic acylcarnitines, as described previously (24) . To further improve chromatographic separation and to enhance peak shapes, the ion pairing agent HFBA was added to the eluents in very low concentrations (0.005%). HFBA was favored over the stronger acid trifluoroacetic acid (TFA) which is more commonly used (9), because TFA causes very strong ion suppression (25) . We could achieve base-line separation of all Calibration was performed by stable isotope dilution. A co-elution of standards and available internal standards was achieved, which is important for compensation of matrix effects and differences in ionization efficiency (16) . LODs and LOQs were sufficient to determine analytes in plasma and/or liver (Table S5 ). In addition, we observed that matrix effects of liver tissue are comparable to other tissue types such as muscle, heart, or kidney tissue, and thus suggest that the method can be applied to other tissues to determine analyte concentrations in these matrices (data not shown). Importantly, extraction of increased tissue quantities (>40mg) does not improve method performance, since this leads to increased noise and reduced signal-to-noise ratios. In general, for comparison of analyte concentrations between samples, it is recommended to extract similar quantities of tissue to reduce variation resulting from matrix effects.
To evaluate LC-MS/MS method performance, we validated our method in plasma and liver samples as described previously (26) . Precisions showed coefficients of variation (CVs) <15% for high-abundant metabolites and CVs <20% for low-abundant compounds. Accuracies displayed CVs of +/-10% with a few exceptions. This is a major improvement/advantage over previously published methods, for which up to 30% variation was reported in plasma (9), or for which no measures were reported at all (11) . We observed that plasma samples were stable when stored for one hour at room temperature previous to preparation. Furthermore, most acylcarnitine species in plasma and liver showed a high post-preparative stability.
We applied our method to plasma and liver samples of streptozotocin-treated insulin-deficient mice.
Streptozotocin is selectively taken up into the pancreas and causes beta-cell toxicity via alkylation, resulting in beta cell necrosis (20) . Streptozotocin-treated mice showed very low circulating insulin levels paralleled by a strong increase in blood glucose and a dramatic decrease in body weight (see Supplementary Table 5) . Calibration lines were generated by plotting the area ratios of analyte/IS against the spiked concentrations. Concentrations in liver are given per mg liver wet weight. IS, internal standard; LOD, limit of detection; LOQ, limit of quantitation; w.w., wet weight Table 4 . Intra-and inter-day precisions 
